Cagrilintide vs GLP-1 Receptor Agonists: Mechanism and Class Compared

The short answer the literature gives

Cagrilintide is a long-acting analogue of amylin, a pancreatic hormone, and a review of its pharmacology described it as an amylin analogue developed for obesity rather than as an incretin medicine (PMID 36883831). GLP-1 receptor agonists are a separate pharmacological class built around glucagon-like peptide-1, and a review of novel GLP-1-based medications grouped them by their shared action at the GLP-1 receptor (PMID 41054801). The two families overlap in the clinical problems they have been studied in — body weight and glycaemic control — and they overlap in some downstream physiology, such as slowed gastric emptying and reduced food intake, but they engage different receptors. For background on the single molecule, see the cagrilintide overview.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medicine, including whether a particular class of therapy is appropriate in an individual case.

What cagrilintide targets

Amylin, also called islet amyloid polypeptide, is co-secreted with insulin from pancreatic beta cells. A review of cagrilintide pharmacology described the molecule as a long-acting amylin analogue engineered for weekly administration and acting on amylin signalling pathways involved in satiety and food intake (PMID 36883831). A broader review of amylin analogues for obesity without diabetes set out the receptor biology of the class, in which amylin signalling is mediated by calcitonin receptor complexes modified by receptor activity-modifying proteins, and discussed how long-acting analogues were developed from that starting point (PMID 39317404).

Researchers writing on amylin analogues have emphasised that the hindbrain, particularly the area postrema, is a principal site of amylin action, and that the physiological consequences described for the class include reduced meal size and increased satiation (PMID 39317404). A pharmacology handbook chapter on drugs for treating obesity placed amylin-based approaches alongside other centrally and peripherally acting agents in the obesity pharmacotherapy landscape (PMID 34783910).

What GLP-1 receptor agonists target

GLP-1 is an incretin hormone released from intestinal L-cells after eating. A review of novel GLP-1-based medications for type 2 diabetes and obesity described the class as acting at the GLP-1 receptor to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying and reduce appetite through central pathways (PMID 41054801). A systematic review and network meta-analysis of GLP-1 receptor agonists in type 2 diabetes compared agents within the class on glycaemic control, body weight and lipid profile, and reported differences between individual agonists on those outcomes (PMID 38286487).

Because the class is defined by its receptor target rather than by a single outcome, the literature on it is wide. A review of multisystem effects of obesity medications discussed outcomes beyond weight loss reported for these drugs, including cardiometabolic endpoints (PMID 42208956), and a review of diabetes and chronic kidney disease discussed the place of GLP-1-based therapy in that population (PMID 41375628).

Mechanism side by side

Structure and molecular design

Native amylin is prone to aggregation, and a review of cagrilintide described the molecule as an engineered long-acting analogue designed for a dosing interval of once weekly in the obesity setting (PMID 36883831). The broader amylin analogue review set out how sequence modification and half-life extension distinguished newer analogues from earlier short-acting amylin-based agents (PMID 39317404).

GLP-1 receptor agonists share a different structural starting point. A review of GLP-1-based medications described how backbone modification and albumin-binding strategies were used across the class to resist enzymatic degradation and extend exposure (PMID 41054801). Both families therefore use comparable medicinal-chemistry strategies for half-life extension while acting on unrelated receptor systems.

Why the two mechanisms have been studied together

Because amylin and GLP-1 signalling converge on appetite regulation through different routes, trials have examined them in combination. A multicentre, randomised, double-blind, active-controlled phase 2 trial evaluated once-weekly cagrilintide 2.4 mg co-administered with once-weekly semaglutide 2.4 mg in people with type 2 diabetes, with semaglutide 2.4 mg alone as the active comparator (PMID 37364590). The study was designed to test whether adding amylin-receptor pharmacology to GLP-1 receptor agonism changed glycaemic and body-weight outcomes, and researchers reported outcomes for the co-administration arm against the single-agent comparator in that population (PMID 37364590).

Reviews of the development landscape have placed that combination within a wider pipeline. A review of phase 2 and phase 3 pipelines for obesity described how GLP-1 receptor agonists were being combined with other mechanisms, including amylin-based agents, in later-stage programmes (PMID 40022548). A clinical review of weight management in obesity similarly described pharmacological combinations as a direction of travel in the field (PMID 40865172).

Regulatory status, stated plainly

Cagrilintide is a prescription medicine. Its evidence base has been generated in company-sponsored randomised clinical trials, including the phase 2 co-administration study in type 2 diabetes described above (PMID 37364590), and reviews have tracked its progress through the obesity development pipeline (PMID 36883831).

GLP-1 receptor agonists are also prescription medicines, and several have been in clinical use long enough to generate large comparative datasets; a network meta-analysis pooled randomised evidence across agents in type 2 diabetes for glycaemic control, body weight and lipid outcomes (PMID 38286487), and a separate systematic review compared semaglutide, liraglutide, orlistat and phentermine for weight loss in people with obesity (PMID 40206909). Questions about which licensed products exist in a given country, and whether any of them is suitable for a particular person, are matters for a prescribing clinician and the relevant national product information.

How the evidence bases differ in maturity

The volume of published comparative evidence is not symmetrical between the two topics. For GLP-1 receptor agonists, the network meta-analysis in type 2 diabetes synthesised randomised trials across multiple agents and outcomes (PMID 38286487), and a review of multisystem effects of obesity medications discussed reported benefits extending beyond weight change (PMID 42208956). For amylin analogues, the available reviews have been framed around present status and future prospects rather than around settled long-term outcome data (PMID 39317404).

That difference matters for interpretation. A comparison of mechanisms is not a comparison of accumulated clinical outcome evidence, and the obesity pharmacotherapy chapter noted that the field has repeatedly revised its assessment of agents as longer-term data arrived (PMID 34783910). Reviews of the obesity pipeline have also cautioned that agents in active development are described by interim data rather than by completed long-term programmes (PMID 40022548).

Tolerability and Adverse Events: What Studies Report

In the phase 2 trial of once-weekly cagrilintide 2.4 mg co-administered with once-weekly semaglutide 2.4 mg in type 2 diabetes, researchers reported that gastrointestinal events were the most frequently observed adverse events across treatment groups (PMID 37364590). The review of cagrilintide pharmacology likewise described gastrointestinal tolerability as the principal reported safety consideration for the amylin analogue in obesity trials (PMID 36883831).

For the GLP-1 receptor agonist class, gastrointestinal effects such as nausea, vomiting and diarrhoea have been the most commonly reported adverse events in synthesised randomised evidence in type 2 diabetes (PMID 38286487), and a systematic review comparing weight-loss pharmacotherapies in obesity also discussed tolerability alongside efficacy for semaglutide and liraglutide (PMID 40206909). Reviews of weight-management pharmacotherapy have described monitoring and clinician supervision as part of how these medicines are used in practice (PMID 40865172). Individual risk assessment, including contraindications and interactions, falls to a prescribing clinician.

What a mechanism comparison cannot settle

• Receptor difference is not outcome difference. Distinct receptor targets explain why amylin analogues and GLP-1 receptor agonists are classified separately (PMID 39317404), but comparative clinical outcomes come from trials, not from pharmacology alone.
• Combination data describe the combination. The phase 2 trial tested co-administration against single-agent semaglutide in type 2 diabetes (PMID 37364590), so its findings describe that specific comparison and population.
• Populations differ. Evidence summarised for type 2 diabetes (PMID 38286487) does not transfer automatically to obesity without diabetes, which the amylin review treated as a distinct question (PMID 39317404).
• The field is moving. Pipeline reviews described multiple agents and combinations still under study (PMID 40022548).

In summary, cagrilintide belongs to the amylin analogue class and GLP-1 receptor agonists belong to the incretin class; the published pharmacology describes complementary rather than identical mechanisms (PMID 36883831, PMID 41054801). Any decision about treatment is a clinical one made with a prescribing physician.

References

• Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity (Cardiology in Review, 2024)
• Amylin analogs for the treatment of obesity without diabetes: present and future (Expert Review of Clinical Pharmacology, 2024)
• Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial (Lancet, 2023)
• Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis (BMJ, 2024)
• Novel GLP-1-based Medications for Type 2 Diabetes and Obesity (Endocrine Reviews, 2026)
• The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines (Expert Opinion on Investigational Drugs, 2025)
• Beyond weight loss: multisystem benefits of obesity medications (The Lancet Diabetes & Endocrinology, 2026)
• Drugs for Treating Obesity (Handbook of Experimental Pharmacology, 2022)
• Comparative Effectiveness of Semaglutide, Liraglutide, Orlistat, and Phentermine for Weight Loss in Obese Individuals: A Systematic Review (Cureus, 2025)
• Weight management treatment in obesity (Medicina Clinica, 2025)
• Diabetes Mellitus and Chronic Kidney Disease: The Future Is Being Surpassed (Journal of Clinical Medicine, 2025)